Chin Lynda
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Nat Rev Cancer. 2003 Aug;3(8):559-70. doi: 10.1038/nrc1145.
Therapeutic resistance and proclivity for metastasis are hallmarks of malignant melanoma. Genetic, epidemiological and genomic investigations are uncovering the spectrum of stereotypical mutations that are associated with melanoma and how these mutations relate to risk factors such as ultraviolet exposure. The ability to validate the pathogenetic relevance of these mutations in the mouse, coupled with advances in rational drug design, has generated optimism for the development of effective prevention programmes, diagnostic measures and targeted therapeutics in the near future.
治疗抵抗和转移倾向是恶性黑色素瘤的标志。遗传学、流行病学和基因组学研究正在揭示与黑色素瘤相关的典型突变谱,以及这些突变与紫外线暴露等风险因素之间的关系。在小鼠中验证这些突变的致病相关性的能力,再加上合理药物设计的进展,为在不久的将来制定有效的预防方案、诊断措施和靶向治疗带来了希望。